menu
    • menu
    [{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gefapixant Citrate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Gefapixant Citrate

    Menu

    Gefapixant Citrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Declines to Approve Merck's Chronic Cough Drug

                            Details : Lyfnua (gefapixant) is an investigational, non-narcotic, oral selective P2X3 receptor antagonist, under development for the treatment of refractory chronic cough or unexplained chronic cough in adults.

                            Brand Name : Lyfnua

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 20, 2023

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merck Receives Positive European Union CHMP Opinion for Gefapixant

                            Details : MK-7264 (gefapixant), an investigational, orally administered, selective P2X3 receptor antagonist, is being developed for the potential treatment of refractory or unexplained chronic cough and was approved in Japan and Switzerland under the brand name Ly...

                            Brand Name : MK-7264

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 21, 2023

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merck Provides U.S. and Japan Regulatory Update for Gefapixant

                            Details : Last week, the Japan Ministry of Health, Labor and Welfare (MHLW) approved LYFNUA® (gefapixant) Tablets 45 mg for adults with refractory or unexplained chronic cough.

                            Brand Name : Lyfnua

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2022

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Merck’s Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Refracto...

                            Details : COUGH-1 and COUGH-2 are international Phase 3, randomized, double-blind, placebo-controlled, studies to evaluate the efficacy and safety of gefapixant in reducing cough frequency in adult participants with refractory or unexplained chronic cough.

                            Brand Name : MK-7264

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2020

                            Lead Product(s) : Gefapixant Citrate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth